Seaport Therapeutics priced its IPO at $18 per share, selling 14.16 million shares, generating $254.9 million in gross proceeds.
The company received a 30‑day option for underwriters to buy an additional 2.124 million shares at the same price.
Seaport’s market cap rose to $64.3 million post‑pricing, with a current ratio of 1.86 indicating strong liquidity.
Shares began trading on Nasdaq Global Select Market under ticker SPTX, with the offering set to close on May 4, 2026.